These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22203487)

  • 21. The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.
    Perricone M; Polverelli N; Martinelli G; Catani L; Ottaviani E; Zuffa E; Franchini E; Dizdari A; Forte D; Sabattini E; Cavo M; Vianelli N; Palandri F
    Oncotarget; 2017 Jun; 8(23):37239-37249. PubMed ID: 28422729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.
    Stein BL; Williams DM; O'Keefe C; Rogers O; Ingersoll RG; Spivak JL; Verma A; Maciejewski JP; McDevitt MA; Moliterno AR
    Haematologica; 2011 Oct; 96(10):1462-9. PubMed ID: 21712540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case of myeloid sarcoma with correlation to JAK2V617F mutation, complicated by myelofibrosis and secondary acute myeloid leukemia.
    Yoshiki Y; Asai T; Ichikawa M; Hangaishi A; Ota S; Imai Y; Takahashi T; Kurokawa M
    Intern Med; 2011; 50(21):2649-52. PubMed ID: 22041374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A role for JAK2 mutations in myeloproliferative diseases.
    Morgan KJ; Gilliland DG
    Annu Rev Med; 2008; 59():213-22. PubMed ID: 17919086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation.
    Spivak JL
    Ann Intern Med; 2010 Mar; 152(5):300-6. PubMed ID: 20194236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombocytosis in rheumatoid arthritis: JAK2V617F-positive essential thrombocythemia.
    Ayvaz OC; Yavasoglu I; Kadikoylu G; Bozkurt G; Bolaman Z
    Rheumatol Int; 2012 Jan; 32(1):269-71. PubMed ID: 21243496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alvarez-Larrán A; Angona A; Martínez-Avilés L; Bellosillo B; Besses C
    Leuk Res; 2012 Mar; 36(3):324-6. PubMed ID: 22001278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
    Passamonti F; Elena C; Schnittger S; Skoda RC; Green AR; Girodon F; Kiladjian JJ; McMullin MF; Ruggeri M; Besses C; Vannucchi AM; Lippert E; Gisslinger H; Rumi E; Lehmann T; Ortmann CA; Pietra D; Pascutto C; Haferlach T; Cazzola M
    Blood; 2011 Mar; 117(10):2813-6. PubMed ID: 21224469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
    Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK2V617F mutations in myeloid malignancies: single center experience.
    Panovska-Stavridis I; Cevreska L; Ivanovski M; Stojanovik A; Lozance M; Matevska N; Dimovski A; Serafimoski V
    Prilozi; 2008 Dec; 29(2):257-67. PubMed ID: 19259051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
    Tefferi A
    Hematology Am Soc Hematol Educ Program; 2006; ():240-5. PubMed ID: 17124067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
    Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
    Akada H; Yan D; Zou H; Fiering S; Hutchison RE; Mohi MG
    Blood; 2010 Apr; 115(17):3589-97. PubMed ID: 20197548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of JAK2 V617F mutation in thalassemia intermedia patients.
    Taher A; Shammaa D; Bazarbachi A; Itani D; Zaatari G; Greige L; Otrock ZK; Mahfouz RA
    Mol Biol Rep; 2009 Jul; 36(6):1555-7. PubMed ID: 18781401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.
    Gau JP; Chen CC; Chou YS; Liu CJ; Yu YB; Hsiao LT; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH
    Blood Cells Mol Dis; 2015 Jun; 55(1):36-9. PubMed ID: 25976465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort.
    Ianotto JC; Chauveau A; Mottier D; Ugo V; Berthou C; Lippert E; Delluc A
    Ann Hematol; 2017 Mar; 96(3):383-386. PubMed ID: 27766390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
    Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JAK2, CALR, and MPL Mutations in Egyptian Patients With Classic Philadelphia-negative Myeloproliferative Neoplasms.
    Soliman EA; El-Ghlban S; El-Aziz SA; Abdelaleem A; Shamaa S; Abdel-Ghaffar H
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e645-e651. PubMed ID: 32591258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
    Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
    Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.